JAMA 318(15):14601470 Nauck MA, Petrie JR, Sesti G, Mannucci E, Courrges JP, Lindegaard ML, Jensen CB, Atkin SL (2016) A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes
The extent of recovery is often less dramatic for older patients, he adds
8.0%, HR 0.80, p 27 kg/m) or obese chronic coronary syndrome patients to reduce cardiovascular mortality, MI, or stroke (Class IIa, Level B) [18]
People with Medical Conditions Affecting Absorption: Conditions like pernicious anaemia , Crohns disease , celiac disease , and gastrectomy reduce the bodys ability to absorb B12 from food, making injections a more reliable option
doi: 10.1038/sj.onc.1210796 67 FrankNYSchattonTFrankMH